Cantonal Hospital Bihac, Bihac, Bosnia and Herzegovina.
Med Arch. 2021 Apr;75(2):158-161. doi: 10.5455/medarh.2021.75.158-161.
Infantile hemangiomas (IH) are the most common vascular, benign tumors of childhood with a prevalence of 4-5%. Due to intense vasculogenesis, they proliferate during infancy, then involute at an unpredictable rate, extent of involution, and quality of residual tissue. Depending on the location, they may be associated with anomalies of other organ systems (PHACE, PELVIS syndroms). In recent decades, knowledge about hemangiomas has improved, and therefore therapeutic possibilities have improved. Today, the non-selective beta blocker-propranolol is considered the drug of first choice in the treatment of infantile hemangiomas. It is desirable to start treatment in the proliferative phase of hemangioma growth for the best possible effect. The dynamics of drug administration, time interval of dose increase and monitoring of patients during treatment vary from one Institution to another and are still the subject of discussion.
We presented the case of a child with infantile hemangioma of the lumbo-sacral region, treated with combination therapy with systemic propranolol and topical timolol, with satisfactory effect in the end.
Propranolol is considered a drug with well-studied side effects and a safety profile. During 6 months of treatment, it leads to complete or almost complete withdrawal of the hemangioma. Treatment should be started in the hemangioma proliferation phase for the best possible therapeutic effect.
婴儿血管瘤（IH）是儿童中最常见的血管良性肿瘤，患病率为 4-5%。由于血管生成活跃，它们在婴儿期增殖，然后以不可预测的速度、消退程度和残留组织质量进行消退。根据位置的不同，它们可能与其他器官系统的异常有关（PHACE、骨盆综合征）。近几十年来，人们对血管瘤的认识有所提高，因此治疗的可能性也有所提高。如今，非选择性β受体阻滞剂-普萘洛尔被认为是治疗婴儿血管瘤的首选药物。为了获得最佳效果，最好在血管瘤生长的增殖期开始治疗。药物给药的动态、剂量增加的时间间隔以及治疗期间患者的监测在不同机构之间存在差异，仍在讨论中。
我们报告了一例腰骶部婴儿血管瘤患儿，采用全身普萘洛尔联合局部噻吗洛尔联合治疗，最终取得满意效果。
普萘洛尔被认为是一种副作用研究充分、安全性良好的药物。在 6 个月的治疗期间，它导致血管瘤完全或几乎完全消退。为了获得最佳的治疗效果，治疗应在血管瘤增殖期开始。
